10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company shows strong product development with new launches and acquisitions, optimistic guidance in spatial biology, and positive market trends. Despite cautious spending and macroeconomic uncertainties, management is confident in their leadership and growth potential, especially in China and Europe. The Q&A session highlighted enthusiasm for new products and strategic positioning against competitors. The market cap suggests moderate sensitivity, leading to a positive stock price prediction.
Key Financial Performance
Total Revenue $149 million, down 2% year-over-year and up 2% sequentially. The decline was attributed to lower average selling prices and macroeconomic challenges.
Consumables Revenue $127.9 million, up 1% year-over-year. Chromium consumables revenue was $92.5 million, down 4%, due to lower average selling prices. Spatial consumables revenue was $35.4 million, up 19%, driven by strong demand for Xenium consumables.
Instrument Revenue $12 million, down 37% year-over-year. Chromium instrument revenue was $4.9 million, down 36%, and spatial instrument revenue was $7.1 million, down 38%, primarily due to lower average selling prices.
Services Revenue $8.1 million, up 29% year-over-year, primarily due to an increase in Xenium service plans.
Geographical Revenue - Americas $79.9 million, down 9% year-over-year, due to continued uncertainty in the U.S. academic and government funding environment.
Geographical Revenue - EMEA $41.6 million, up 10% year-over-year, driven by strong spatial consumables performance.
Geographical Revenue - APAC $27.5 million, up 6% year-over-year, but down 14% sequentially due to a Q2 customer-driven pull forward in China.
Gross Profit $100.3 million, down from $106.4 million in the prior year. Gross margin decreased to 67% from 70%, primarily due to changes in product mix and higher inventory write-downs, partially offset by lower royalties and warranty costs.
Operating Expenses $132.5 million, down from $147.9 million in the prior year, driven by lower personnel and outside legal expenses.
Operating Loss $32.2 million, compared to $41.5 million in the prior year, reflecting improved cost management.
Net Loss $27.5 million, compared to $35.8 million in the prior year, reflecting improved cost management.
Cash Position $482 million, up $35 million from the prior quarter, reflecting strong cost management and cash generation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Xenium consumables: Achieved double-digit year-over-year revenue growth driven by strong demand. Customers appreciate its exceptional performance and broad applications.
Chromium Flex: Launched next-generation version with improved sensitivity, scalability, and automation-friendly workflows. Supports AI-driven initiatives like virtual cell modeling.
Xenium protein: New addition to Xenium platform enabling detection of RNA and proteins in the same cell and tissue section. Simplifies workflows and accelerates translational discovery.
FFPE dissociation protocol: Developed scalable protocol for high-volume studies, improving efficiency and throughput for translational research.
Geographical revenue performance: Americas revenue declined 9% year-over-year due to funding uncertainty. EMEA revenue grew 10%, driven by spatial consumables. APAC revenue increased 6% year-over-year but declined sequentially due to prior pull-forward in China.
Customer spending behavior: Spending remains cautious, particularly for capital expenditures, due to persistent funding uncertainty.
Revenue performance: Total revenue for Q3 2025 was $149 million, exceeding guidance. Consumables revenue grew 1%, while instrument revenue declined 37%.
Cost management: Operating expenses decreased to $132.5 million, driven by lower personnel and legal expenses. Ended the quarter with $482 million in cash, reflecting strong cost management.
Partnership with Anthropic: Integrated Claude for Life Sciences to address data analysis bottlenecks, making analysis more accessible through conversational interfaces.
Collaboration with CLISEQ and Weizmann Institute: Focused on translational research and clinical applications, using Chromium to identify cell signatures for hematologic disorders.
Virtual cell initiatives: Supporting AI-driven virtual cell modeling, which is expected to transform science and drug discovery.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Challenges: The company is navigating persistent macroeconomic challenges, including funding pressures and policy uncertainty, which are impacting customer spending behavior, particularly for capital expenditures.
Revenue Decline in Key Segments: Total revenue for the third quarter was down 2% year-over-year, with significant declines in instrument revenue (down 37%) and Chromium instrument revenue (down 36%), primarily due to lower average selling prices.
Geographic Revenue Pressures: Revenue in the Americas declined by 9% year-over-year, driven by uncertainty in the U.S. academic and government funding environment.
Gross Margin Decline: Gross margin decreased to 67% from 70% in the prior year, primarily due to changes in product mix and higher inventory write-downs.
Customer Spending Caution: Customer spending behavior remains cautious, with no anticipated year-end budget acceleration, reflecting ongoing funding uncertainties and economic pressures.
Operational Losses: The company reported an operating loss of $32.2 million for the third quarter, though this was an improvement from the prior year's loss of $41.5 million.
Inventory Write-Downs: Higher inventory write-downs contributed to the decline in gross margin, indicating potential inefficiencies or challenges in inventory management.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook for Q4 2025: Anticipated revenue range of $154 million to $158 million, representing 5% growth compared to Q3 at the midpoint.
Customer Purchasing Behavior: No material change in customer purchasing behavior is anticipated, and no year-end budget acceleration is expected.
Balance Sheet and Investment Strategy: Strong balance sheet with $482 million in cash, providing flexibility to invest in innovation, advance strategic initiatives, and support long-term growth.
Market Conditions: Continued cautious spending behavior, particularly for capital expenditures, due to persistent funding uncertainty.
Product Development and Adoption: Focus on advancing the innovation roadmap, driving greater adoption of products, and removing barriers to access.
Virtual Cell and AI-driven Initiatives: Anticipation of significant growth in virtual cell efforts and large perturbation studies, with technologies expected to scale by orders of magnitude.
Translational Research and Clinical Applications: Increasing focus on translational research and clinical applications, including collaborations like the PERIBLOOD clinical trial for hematologic disorder detection.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you walk through how much of the 5% sequential pickup in the guide is expected to come from instruments versus consumables, and what assumptions are built into the Q4 guide regarding the government shutdown?
A:The company is not anticipating a big year-end budget flush but expects a slight uptick on the instrument side in Q4 compared to Q3. The government shutdown has been factored into the Q4 guidance, with NIH Intramural being a low percentage of the overall business.
Q:What does the quarter-over-quarter improvement mean for 2026, and is it reasonable to expect growth in 2026 adjusted for royalty payments?
A:Management stated it is too early to discuss 2026 due to macroeconomic uncertainties and limited visibility among customers. They anticipate the first half of 2026 to look similar to the second half of 2025 but refrained from providing specific guidance.
Q:How should we think about spatial consumables in Q4 and into 2026, given the flat-to-slightly-down performance in Q3?
A:Spatial consumables had a pull-forward in Asia from Q3 to Q2, but normalized trends show a sequential step-up in Q3. Management expects spatial consumables to continue performing well, with positive trends pointing in the right direction.
Q:What is the medium- to near-term impact of the GEM-X Flex v2 product, given its lower price per sample and increased flexibility?
A:The GEM-X Flex v2 product offers significant flexibility and lower per-sample costs (20%-30% drop in average reaction price). Management expects volume growth to offset the lower pricing over time, consistent with their strategy and customer feedback.
Q:Can you provide insights into the contributions from Xenium and Visium for spatial consumables and user dynamics per system?
A:Management noted increasing enthusiasm for Xenium, with consistent upticks in usage and per-instrument pull-through. While they did not provide specific pull-through metrics, they emphasized that Xenium is trending positively compared to Visium.
Q:What is the company’s response to a competitor’s acquisition of an instrument-free solution company and its aspirations in single-cell technology?
A:Management views the acquisition as validation of the single-cell space's potential. They emphasized their technology leadership, product performance, and customer loyalty, stating that they expect to maintain their leadership position despite competition.
Q:Can you discuss the strong spatial performance in Europe and its sustainability?
A:Management cautioned against over-indexing on any particular quarter or region, noting that spatial consumables and Xenium consumables performed well in Europe as part of broader global trends. They expect these trends to generally continue.
Q:What are the company’s observations on the China market, given the pull-forward in Q2 and year-over-year growth?
A:The company has seen good demand and improved execution in China following changes to their go-to-market strategy. While they are cautious about long-term visibility, they are currently seeing robust business in the region.
Q:Can you elaborate on early adoption trends for Xenium protein and multiomic workflows, and which end markets are showing the strongest demand?
A:The Xenium protein product has received positive initial feedback for its ability to measure proteins and RNA from the same sample. Management highlighted strong differentiation for Xenium and noted promising trends in translational applications and large-scale experiments.
Q:What is needed for single-cell consumables to recover going into 2026?
A:Management is encouraged by sequential growth in reaction volumes and revenue for single-cell consumables. They acknowledge pricing headwinds from new product introductions but expect volume growth to continue driving recovery.
Q:What is the outlook for Visium, given the increasing preference for Xenium?
A:Management noted a trend of increasing enthusiasm for Xenium over Visium, driven by its superior performance and customer feedback. They expect this trend to continue as researchers adopt Xenium for its capabilities.
Q:What are the company’s observations on pharma behavior and budget constraints as the year ends?
A:Pharma remains a challenging segment due to macroeconomic uncertainties and policy questions affecting early-stage research investments. While there are positive trends in large-scale experiments and translational applications, management remains cautious about near-term visibility.
Q:What is the elasticity of Chromium with the launch of the recent Flex assay, and what growth can be expected for single-cell in the interim?
A:Management is encouraged by consistent volume growth aligned with their strategy. They are still assessing the steady-state impact of new products but are optimistic about the long-term growth potential of single-cell consumables.
Q:What is the impact of the NextGen end-of-life transition to GEM-X on the P&L?
A:The transition to GEM-X is largely complete, with minimal remaining impact on the P&L. Most effects have already been accounted for.
Q:Will customers resist purchasing Chromium instruments when pricing returns to normal levels after temporary discounts?
A:Management believes the unique circumstances of the past year do not set a precedent for future pricing. They expect customers to continue purchasing based on product value and performance.
Q:What is the adoption rate of Xenium’s 5K panel, and how has it contributed to consumable growth?
A:The 5K panel has been a significant driver of Xenium consumable growth, contributing to higher price per run and increased adoption.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or clarity on 2026 guidance, citing macroeconomic uncertainties and limited visibility. They also refrained from quantifying the percentage of customers using Flex and Xenium together, as well as specific pull-through metrics for Xenium and Visium.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
APAC customer
Americas uncertainty
CLISEQ
Chip Multiplexing
Chromium consumables
Principal
Relations Strategic
Strategic Finance
Xenium consumables
Xenium protein
access
analysis bottleneck
approach
biology year
blood
cell assay
cell effort
condition
digit
driver
experiment
field
flexibility
generation
insight
momentum cell
need
perturbation
plate
protocol
road map
royalty
scientist
selling price
tissue section
workflow
TXG Transcript
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed outlook. Financial performance is stable, but growth is limited due to constrained capital expenditure and muted market conditions. The Atera launch is promising, yet its impact is delayed until 2027. Cost management is commendable, but inflationary pressures may affect margins. The Q&A reveals cautious optimism around AI and Atera, but lacks specifics on scaling and pricing strategies. Overall, the strategic plan and market conditions suggest a neutral impact on stock price, with no strong catalysts for significant movement in either direction.
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
Positive2-14
The earnings call indicates strong financial health with a $482 million cash reserve and a focus on product innovation and market expansion. The Q&A reveals confidence in spatial consumables and biopharma revenue growth, despite CapEx headwinds. The strategic focus on AI and translational research, along with a strong balance sheet, supports positive sentiment. The market cap suggests moderate stock volatility, leading to a predicted positive stock price movement of 2% to 8% over the next two weeks.
10x Genomics, Inc. (TXG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
TXG Slides
TXG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
